These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 12586669)

  • 41. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales.
    Trotter CL; Ramsay ME; Gray S; Fox A; Kaczmarski E
    Lancet Infect Dis; 2006 Oct; 6(10):616-7; author reply 617-8. PubMed ID: 17008169
    [No Abstract]   [Full Text] [Related]  

  • 42. Editorial commentary: fifteen years of protection by meningococcal C conjugate vaccines: lessons from disease surveillance.
    Maiden MC; MacLennan JM
    Clin Infect Dis; 2014 Nov; 59(9):1222-4. PubMed ID: 25069870
    [No Abstract]   [Full Text] [Related]  

  • 43. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 44. Can we control all-cause meningococcal disease in Europe?
    Sadarangani M; Pollard AJ
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S103-S112. PubMed ID: 27129415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
    J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
    Pace D; Pollard AJ
    Arch Dis Child; 2007 Oct; 92(10):909-15. PubMed ID: 17895339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A; Cano R; García M; Mateo Sd
    Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Northland emergency meningococcal C vaccination programme.
    Mills C; Penney L
    N Z Med J; 2013 Apr; 126(1373):30-9. PubMed ID: 23797074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.
    Wang X; Shutt KA; Vuong JT; Cohn A; MacNeil J; Schmink S; Plikaytis B; Messonnier NE; Harrison LH; Clark TA; Mayer LW
    J Infect Dis; 2015 Jun; 211(12):1887-94. PubMed ID: 25556253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study.
    Hill DM; Lucidarme J; Gray SJ; Newbold LS; Ure R; Brehony C; Harrison OB; Bray JE; Jolley KA; Bratcher HB; Parkhill J; Tang CM; Borrow R; Maiden MC
    Lancet Infect Dis; 2015 Dec; 15(12):1420-8. PubMed ID: 26515523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.
    Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK
    Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meningococcal vaccines: WHO position paper, November 2011.
    Wkly Epidemiol Rec; 2011 Nov; 86(47):521-39. PubMed ID: 22128384
    [No Abstract]   [Full Text] [Related]  

  • 54. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enter B and W: two new meningococcal vaccine programmes launched.
    Ladhani SN; Ramsay M; Borrow R; Riordan A; Watson JM; Pollard AJ
    Arch Dis Child; 2016 Jan; 101(1):91-5. PubMed ID: 26672098
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meningococcal vaccination in pregnancy.
    Abu Raya B; Sadarangani M
    Hum Vaccin Immunother; 2018 May; 14(5):1188-1196. PubMed ID: 29485347
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: a population-based study, 2001-2013.
    Moraes C; Moraes JC; Silva GD; Duarte EC
    Mem Inst Oswaldo Cruz; 2017 Apr; 112(4):237-246. PubMed ID: 28327788
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conjugate vaccine-induced immunological priming is not protective against acute meningococcal C infection.
    Spoulou VI; Moschou CK; Tzanakaki G; Theodoridou MC
    Vaccine; 2007 Oct; 25(41):7012-3. PubMed ID: 17707961
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.